A neomorphic protein interface catalyzes covalent inhibition of RAS <sup>G12D</sup> aspartic acid in tumors
Caroline E. Weller(Revolution Medicines (United States)), David Wildes(Revolution Medicines (United States)), Anthony N. Milin(Revolution Medicines (United States)), Abby Marquez(Revolution Medicines (United States)), Benjamin J. Maldonato(University of Washington), Hanrong Feng(Dana-Farber Cancer Institute), Diane F. Eilerts(San Jose State University), Connor J. Hennessey(Broad Institute), Matthew Holderfield(Revolution Medicines (United States)), Adrian L. Gill(AstraZeneca (Sweden)), Eejung Kim(Broad Institute), Jacqueline A.M. Smith(Revolution Medicines (United States)), G. Leslie Burnett(Revolution Medicines (United States)), Julien Dilly(Massachusetts Institute of Technology), Sujata Chakraborty(University of Washington), Seema Chugh(Broad Institute), Kyle J. Seamon(Revolution Medicines (United States)), Elena S. Koltun(Revolution Medicines (United States)), Shelby L. Steele(Revolution Medicines (United States)), John E. Knox(Revolution Medicines (United States)), Brian M. Wolpin(Harvard University), Nicole A. Vita(Revolution Medicines (United States)), Jennifer A. Roth(Broad Institute), Jingjing Jiang(Revolution Medicines (United States)), Zhican Wang(Revolution Medicines (United States)), Jessica N. Spradlin(Revolution Medicines (United States)), Mallika Singh(Revolution Medicines (United States)), William C. Hahn(Broad Institute), Matthew G. Rees(Broad Institute), Andrew J. Aguirre(Broad Institute), Lingyan Jiang(Revolution Medicines (United States)), Ciara Helland(Revolution Medicines (United States)), Tamar Bar Ziv(Revolution Medicines (United States)), Dongyu Zhang(Revolution Medicines (United States)), Zhengping Wang(Shandong University), Phuong Uyen Dinh(Revolution Medicines (United States)), Yunming Mu(Revolution Medicines (United States)), Junning Wang(Dana-Farber Cancer Institute), Andrea Gould(Revolution Medicines (United States)), Melissa M. Ronan(Broad Institute)
Cited by 31
Related Papers
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
|Nature Medicine|2015|1.4k
Activated Kras and <i>Ink4a/Arf</i> deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
|Genes & Development|2003|1k